<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04311762</url>
  </required_header>
  <id_info>
    <org_study_id>00000613</org_study_id>
    <nct_id>NCT04311762</nct_id>
  </id_info>
  <brief_title>Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer</brief_title>
  <official_title>Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Vermont Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to identify the maximum tolerated dose of endobronchial&#xD;
      ultrasound-guided transbronchial injection (EBUS-TBNI) of cisplatin for Stage IV lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple studies have demonstrated feasibility and safety of delivering cisplatin directly&#xD;
      into lung tumors using endobronchial ultrasound guided-transbronchial needle injection&#xD;
      (EBUS-TBNI). This technique relies on the use of a bronchoscope with an integrated ultrasound&#xD;
      transducer allowing real-time visualization of, and delivery of cisplatin into, tumors lying&#xD;
      in proximity to the central airways. Prior work has utilized this technique to treat loco&#xD;
      regional recurrence in a previously radiated field. The goal of the current study is to&#xD;
      identify the initial dose for intratumoral cisplatin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Lung Cancer Metastatic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Intratumoral delivery of cisplatin via bronchoscopy (endobronchial ultrasound)</description>
    <other_name>Platinol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age 18 years or above&#xD;
&#xD;
        Eastern Cooperative Oncology Group (ECOG) performance score 0-2&#xD;
&#xD;
        Have known or suspected metastatic NSCLC at time of enrollment (including patients who&#xD;
        progress on initial therapy or are found to have metastatic disease during therapy and are&#xD;
        not excluded based on 8.2 below).&#xD;
&#xD;
        Ability and willingness to provide informed consent&#xD;
&#xD;
        Rapid on-site cytopathologic examination (ROSE) performed during the procedure returns&#xD;
        likely NSCLC (informed consent will occur prior to the procedure). No research procedures&#xD;
        will be performed if ROSE is non-diagnostic.&#xD;
&#xD;
        A CT scan of the chest (with or without contrast) within the prior 3 months.&#xD;
&#xD;
        The presence of an EBUS accessible target site. These may be primary lung cancers or&#xD;
        metastatic sites (including when a lymph node station has been replaced by metastatic&#xD;
        tumor), that are accessible by EBUS&#xD;
&#xD;
        Patients must have adequate organ and marrow function as defined below:&#xD;
&#xD;
          -  Leukocytes ≥3,000/mcL&#xD;
&#xD;
          -  Platelets ≥100,000/mcL&#xD;
&#xD;
          -  Total bilirubin ≤ institutional upper limit of normal (ULN)&#xD;
&#xD;
          -  AST(SGOT)/ALT(SGPT) ≤ institutional ULN&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) ≥60 mL/min/1.73 m2 via CKD EPI)&#xD;
&#xD;
        Patients with a prior or concurrent malignancy whose natural history or treatment does not&#xD;
        have the potential to interfere with the safety or efficacy assessment of the&#xD;
        investigational regimen are eligible for this trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Use of an investigational agent in prior 30 days&#xD;
&#xD;
        Pregnancy/lactation&#xD;
&#xD;
        Treatment with cytotoxic chemotherapy within the past 30 days&#xD;
&#xD;
        Prior (within the last 12 months) or ongoing radiation treatment to the study NSCLC&#xD;
&#xD;
        Allergy to cisplatin or its derivatives&#xD;
&#xD;
        Patient not appropriate for the research study based on physician discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C. Matthew Kinsey, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Burns</last_name>
    <phone>(802) 656-8307</phone>
    <email>stephanie.burns@uvmhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Burns</last_name>
      <phone>802-656-8307</phone>
      <email>stephanie.burns@uvmhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 14, 2020</study_first_submitted>
  <study_first_submitted_qc>March 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>C. Matthew Kinsey MD, MPH</investigator_full_name>
    <investigator_title>Director, Interventional Pulmonary</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

